HighTower Advisors
CATX icon

HighTower Advisors’s Perspective Therapeutics CATX Stock Holding History

HighTower Advisors’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$83.5K Sell
20,027
-16,855
-46% -$71.2K ﹤0.01% 3658
2025
Q4 		$101K Buy
36,882
+7
+0% +$20 ﹤0.01% 3506
2025
Q3 		$126K Sell
36,875
-164,711
-82% -$600K ﹤0.01% 3494
2025
Q2 		$693K Hold
201,586
– – ﹤0.01% 2269
2025
Q1 		$429K Buy
201,586
+23,475
+13% +$70.5K ﹤0.01% 2585
2024
Q4 		$568K Buy
178,111
+36,875
+26% +$301K ﹤0.01% 2375
2024
Q3 		$1.89M Hold
141,236
– – ﹤0.01% 1553
2024
Q2 		$1.41M Buy
141,236
+8,012
+6% +$116K ﹤0.01% 1647
2024
Q1 		$1.58M Hold
133,224
– – ﹤0.01% 1547
2023
Q4 		$536K Buy
133,224
+18,520
+16% +$52.1K ﹤0.01% 2270
2023
Q3 		$314K Hold
114,704
– – ﹤0.01% 2562
2023
Q2 		$766K Hold
114,704
– – ﹤0.01% 1906
2023
Q1 		$732K Hold
114,704
– – ﹤0.01% 1853
2022
Q4 		$283K Buy
+114,704
New +$378K ﹤0.01% 2508
2021
Q2 		– Sell
-1,907
Closed -$21K – 3184
2021
Q1 		$21K Buy
+1,907
New +$28.8K ﹤0.01% 2896

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighTower Advisors's CATX Position: Q1 2026 in Review

HighTower Advisors reduced its Perspective Therapeutics (CATX) stake by 46% in Q1 2026, selling an estimated $71.2K and leaving 20,027 shares worth $83.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3658.

HighTower Advisors first reported a position in CATX in Q1 2021 and has held it in 15 quarters since. The position peaked at $1.89M in Q3 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • HighTower Advisors held 20,027 shares of Perspective Therapeutics worth $83.5K as of Q1 2026.
  • HighTower Advisors sold 16,855 Perspective Therapeutics shares in Q1 2026, an estimated $71.2K.
  • Perspective Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3658 holding.
  • HighTower Advisors first reported a position in Perspective Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • HighTower Advisors's Perspective Therapeutics position peaked at $1.89M in Q3 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.